Dr. Dayao Zhao, Former Head of Pfizer China R&D Center, Appointed CEO of YouBio Medicine

Beijing, China – September 23, 2019 – Eucure Technology (Beijing) Co., Ltd. (“Eucure”), an innovative biotechnology company focused on the field of immunotherapy with strong clinical development capabilities and dedicated to addressing unmet clinical needs, today announced the appointment of Dr. Dayao Zhao as Chief Executive Officer, who will assume full responsibility for all company operations.

Dr. Zhao Dayao

Dr. Zhao Dayao has dedicated over 25 years to the pharmaceutical R&D industry, including a decade as the head of R&D operations in China and the Asia-Pacific region for a leading multinational pharmaceutical company. He possesses extensive and distinguished integrated management expertise in new drug clinical development, strategic planning, commercial operations, and corporate management.

Prior to joining Eucure, he served as General Manager of Pfizer China R&D Center and concurrently as Head of Pfizer China Drug Development Team since 2016.

During this period, he led a research and development team of over 1,000 employees at Pfizer, launching a series of initiatives to optimize and enhance clinical development processes. These efforts transformed the China R&D Center into a key global hub for data processing, quality control, and drug safety, elevating its status as a critical R&D nexus for both the global organization and the Asia-Pacific region, thereby solidifying its position as one of the largest R&D centers operated by multinational pharmaceutical companies in China.

Prior to joining Pfizer, Dr. Dayao Zhao served as Vice President of Johnson & Johnson China and Head of Research, Development, and Scientific Affairs for the region. He established a clear vision for R&D and scientific affairs at Johnson & Johnson China to support the company’s new development strategy, and merged Johnson & Johnson China with its Asian R&D Center (Shanghai) to create a unified, new Chinese R&D team. Before joining Johnson & Johnson China, he was Vice President of Genzyme Corporation and Head of Clinical Development and Regulatory Affairs for the Asia-Pacific region. He began his career in new drug development in 1993 when he joined Pfizer’s R&D center in the United States.

Dr. Zhao Dayao has also played a significant role in shaping policy proposals in China. Meanwhile, he maintains close collaborations with government agencies, the Chinese Association of Foreign Pharmaceutical Enterprises, and other industry associations, and served as the Chairman of the Chinese Drug Information Association in 2015.

“Dr. Zhao Dayao possesses exceptional experience in managing the full lifecycle of clinical R&D. In just the past six years, he has led the completion of hundreds of clinical trials and facilitated the registration and market launch of numerous new drugs. His profound understanding of clinical development, coupled with strong leadership capabilities, has enabled him to rapidly build a robust clinical development team, ensuring the efficient execution of the clinical phase of new drug development and delivering tangible, effective therapies to patients. This will provide crucial momentum for the next stage of Eucure’s growth,” stated Dr. Ni Jian, Founder of Eucure.

“I am deeply impressed by Eucure’s R&D strategy and the achievements it has made over the past three years,” said Dr. Zhao Dayao. “I share Eucure’s vision of becoming a world-class, top-tier, R&D-driven innovative biotechnology company, and I look forward to working with the Eucure team to jointly develop innovative drugs that meet the clinical needs of patients in China and around the globe.”

Dr. Zhao Dayao holds a Ph.D. in Neurobiology/Molecular Biology from Harvard Medical School in the United States, as well as a Doctor of Medicine (M.D.) degree in Neurology/Pediatrics from Peking University Health Science Center.

Eucure Biopharma is an innovative biotechnology company rooted in China with a global perspective. The company’s founders and core team possess extensive experience in new drug development. Eucure focuses on developing innovative antibody drugs with independent intellectual property rights. Leveraging a robust clinical development team and rich clinical development expertise, the company is dedicated to creating innovative therapies that meet clinical needs for patients in China and worldwide.

Eucure focuses on the field of immunotherapy, building a robust R&D pipeline targeting more than ten therapeutic targets. The submission of Investigational New Drug (IND) applications for two pipelines in the United States, the imminent clinical trial applications for three additional pipelines, and the collaborative development of one pipeline have laid a solid foundation for Eucure’s growth.